Adrianus J. de Langen

3.3k citations

64 papers · 931 indexed · h-index 18

Oncology top 5%
- Lung Cancer Research Studies 17
- Colorectal Cancer Treatments and Studies 15
- Cancer Immunotherapy and Biomarkers 11
Pulmonary and Respiratory Medicine top 5%
- Lung Cancer Treatments and Mutations 48
- Lung Cancer Diagnosis and Treatment 10
Radiology, Nuclear Medicine and Imaging top 5%
- Radiomics and Machine Learning in Medical Imaging 10
- Medical Imaging Techniques and Applications 10
Cancer Research
- Cancer Genomics and Diagnostics 10
Genetics

Co-authors: Egbert F. Smit Ronald Boellaard Otto S. Hoekstra Anna-Larissa N. Niemeijer Erik Thunnissen Kim Monkhorst Marc C. Huisman Elisa Giovannetti
Cited by: Oncology Pulmonary and Respiratory Medicine Radiology, Nuclear Medicine and Imaging
Journals: Nature Medicine (1 paper)Journal of Clinical Oncology (8 papers)The Lancet Oncology (1 paper)
Partner nations: Netherlands United States Japan

In The Last Decade

Adrianus J. de Langen

59 papers receiving 921 citations

Peers

Countries citing papers authored by Adrianus J. de Langen

Since Specialization

Citations

This map shows the geographic impact of Adrianus J. de Langen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Adrianus J. de Langen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Adrianus J. de Langen more than expected).

Fields of papers citing papers by Adrianus J. de Langen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Adrianus J. de Langen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Adrianus J. de Langen. The network helps show where Adrianus J. de Langen may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Adrianus J. de Langen, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Adrianus J. de Langen Line = papers co-authored together Adrianus J. de Langen links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	ORCHARD: Osimertinib Plus Necitumumab in Patients With Epidermal Growth Factor Receptor–Mutated Advanced Non–Small Cell Lung Cancer With a Secondary Epidermal Growth Factor Receptor Alteration Whose Disease Had Progressed on First-Line Osimertinib JCO Precision Oncology ·Jonathan W. Riess,Adrianus J. de Langen,Santiago Ponce,Sarah B. Goldberg,Zofia Piotrowska,Jonathan W. Goldman,Xiuning Le,Byoung Chul Cho,Yasuto Yoneshima,Helen Ambrose,Riccardo Cavazzina,Kwan Ho Tang,James Y. Lau,Helena A. Yu	2025	4
2	Improving the diagnosis of leptomeningeal metastases by molecular profiling of cell-free DNA from cerebrospinal fluid European Journal of Cancer ·Berit M. H. van Linder,Dieta Brandsma,Els Verhoeven,Lisa Jongejan,Kim Monkhorst,Adrianus J. de Langen,Daan van den Broek,Dick Pluim,Tom van Wezel,Emma van Kessel,Mirjam C. Boelens	2025	1
3	Physiologically Based Pharmacokinetic Model of Tyrosine Kinase Inhibitors to Predict Target Site Penetration, with PET‐Guided Verification CPT Pharmacometrics & Systems Pharmacology ·Suzanne van der Gaag,Tamara Jordens,Maqsood Yaqub,Robbin Grijseels,Daan W. van Valkengoed,Evelien N. de Langen,Ruben van den Broek,Victor L. Thijssen,Adrianus J. de Langen,Mathilde C.M. Kouwenhoven,Idris Bahce,Bart A. Westerman,N. Harry Hendrikse,Imke H. Bartelink	2025	1
4	Analytical and Clinical Validation of the Plasma-Based Guardant360 CDx Test for Assessing HER2 (ERBB2) Mutation Status in Patients with Non–Small-Cell Lung Cancer for Treatment with Trastuzumab Deruxtecan in DESTINY-Lung01/02 Journal of Molecular Diagnostics ·Zhenhao Qi,Shinya Tokuhiro,Justin I. Odegaard,Sara Wienke,Maha Karnoub,Wenqin Feng,Ryota Shiga,Egbert F. Smit,Yasushi Goto,Adrianus J. de Langen,Kōichi Goto,Kaline Pereira,Shirin Khambata‐Ford	2025	1
5	Osimertinib Plus Savolitinib in Patients With EGFR-Mutated Advanced NSCLC With MET Alterations After First-Line Osimertinib: Clinical Outcomes, Safety, and Biomarker Analysis: A Brief Report Journal of Thoracic Oncology ·Xiuning Le,Christina S. Baik,Byoung Chul Cho,Jonathan W. Riess,Zofia Piotrowska,Adrianus J. de Langen,Sarah B. Goldberg,Jonathan W. Goldman,Noemı́ Reguart,Yoshimasa Shiraishi,Helen Ambrose,Paula G. Fraenkel,Brayan Merchan Ruiz,Paul E. Smith,Kwan Ho Tang,Helena A. Yu	2025	0
6	Safety, Efficacy, and Biomarker Analysis of Crizotinib in MET-Mutated Non–Small Cell Lung Cancer—Results from the Drug Rediscovery Protocol Clinical Cancer Research ·Karlijn Verkerk,Tijmen J.W.T. van der Wel,Laurien J. Zeverijn,Birgit S. Geurts,Ilse A.C. Spiekman,Gijs F. de Wit,Paul Roepman,Anne M.L. Jansen,Vincent van der Noort,Egbert F. Smit,Ann Hoeben,Lizza Hendriks,Michel M. van den Heuvel,Berber Piet,Gerarda J.M. Herder,Sayed M.S. Hashemi,Hans Gelderblom,Henk M.W. Verheul,Emile E. Voest,Adrianus J. de Langen	2024	1
7	Survival difference between patients with single versus multiple metastatic lymph nodes and the role of histology in pathological stage II-N1 non-small cell lung cancer Acta chirurgica Belgica ·Julianne Cynthia de Ruiter,Adrianus J. de Langen,Kim Monkhorst,Alexander Veenhof,Houke M. Klomp,Jasper Smit,Egbert F. Smit,Ronald Damhuis,Koen J. Hartemink	2024	1
8	Trastuzumab deruxtecan (T-DXd) in patients with HER2-mutant metastatic non–small cell lung cancer (mNSCLC): Final analysis results of DESTINY-Lung02. Journal of Clinical Oncology ·Pasi A. Jänne,Yasushi Goto,Toshio Kubo,Kiichiro Ninomiya,Sang‐We Kim,David Planchard,Myung‐Ju Ahn,Egbert F. Smit,Adrianus J. de Langen,M. Pérol,Elvire Pons‐Tostivint,Silvia Novello,Hidetoshi Hayashi,Junichi Shimizu,Dong‐Wan Kim,Kaline Pereira,Fu-Chih Cheng,Ayumi Taguchi,Yingkai Cheng,Kōichi Goto	2024	4
9	Osimertinib-induced DNA resistance mutations in cerebrospinal fluid of epidermal growth factor receptor-mutated non-small-cell lung carcinoma patients developing leptomeningeal metastases: Osimertinib Resistance Analysis-leptomeningeal metastases study Neuro-Oncology ·Tijmen J.W.T. van der Wel,Mirjam C. Boelens,M. Jebbink,Sietske A. Smulders,Klaar W Maas,Merel J.A. Luitse,Annette Compter,Robin P B Boltjes,Nik Sol,Kim Monkhorst,Daan van den Broek,Egbert F. Smit,Adrianus J. de Langen,Dieta Brandsma	2024	5
10	Trastuzumab-Emtansine and Osimertinib Combination Therapy to Target HER2 Bypass Track Resistance in EGFR Mutation-Positive NSCLC JTO Clinical and Research Reports ·M. Jebbink,Adrianus J. de Langen,Kim Monkhorst,Mirjam C. Boelens,Daan van den Broek,Vincent van der Noort,Cornedine J. de Gooijer,M. Mahn,Anthonie J. van der Wekken,Lizza Hendriks,Sayed M.S. Hashemi,Marthe S. Paats,Anne‐Marie C. Dingemans,Egbert F. Smit	2023	19
11	Chemotherapy for patients with EGFR-mutated NSCLC after progression on EGFR-TKI’s: Exploration of efficacy of unselected treatment in a multicenter cohort study Lung Cancer ·C. Steendam,Sophie M. Ernst,Sushil K. Badrising,Marthe S. Paats,Joachim G.J.V. Aerts,Adrianus J. de Langen,Anne‐Marie C. Dingemans	2023	10
12	A qualitative study on the healthcare experiences of adolescents and young adults (AYA) with an uncertain or poor cancer prognosis Supportive Care in Cancer ·Vivian W. G. Burgers,Milou J. P. Reuvers,Martin Taphoorn,Marleen Kok,Adrianus J. de Langen,Martin J. van den Bent,Simone A. M. M. Frissen,Niels C. G. L. Harthoorn,Annemiek Dickhout,Olga Husson,Winette T.A. van der Graaf	2023	3
13	Blood platelet RNA profiles do not enable for nivolumab response prediction at baseline in patients with non-small cell lung cancer Tumor Biology ·Mirte Muller,Myron G. Best,Vincent van der Noort,T. Jeroen N. Hiltermann,Anna-Larissa N. Niemeijer,Edward P. Post,Nik Sol,Sjors G. J. G. In ‘t Veld,Tineke Nogarede,Lisanne E. Visser,Robert D. Schouten,Daan van den Broek,Karlijn Hummelink,Kim Monkhorst,Adrianus J. de Langen,Ed Schuuring,Egbert F. Smit,Harry J.M. Groen,Thomas Würdinger,Michel M. van den Heuvel	2023	1
14	Exposure–Response Analysis of Osimertinib in EGFR Mutation Positive Non-Small Cell Lung Cancer Patients in a Real-Life Setting Pharmaceutical Research ·René J. Boosman,M. Jebbink,Wouter B. Veldhuis,Stefanie L. Groenland,Bianca van Veggel,Pim Moeskops,Adrianus J. de Langen,Jos H. Beijnen,Egbert F. Smit,Alwin D. R. Huitema,Neeltje Steeghs	2022	14
15	Limited evolution of the actionable metastatic cancer genome under therapeutic pressure Nature Medicine ·Joris van de Haar,Louisa R. Hoes,Paul Roepman,Martijn P. Lolkema,Henk M.W. Verheul,Hans Gelderblom,Adrianus J. de Langen,Egbert F. Smit,Edwin Cuppen,Lodewyk F.A. Wessels,Emile E. Voest	2021	36
16	Biomarker-Directed Phase II Platform Study in Patients With EGFR Sensitizing Mutation-Positive Advanced/Metastatic Non-Small Cell Lung Cancer Whose Disease Has Progressed on First-Line Osimertinib Therapy (ORCHARD) Clinical Lung Cancer ·Helena A. Yu,Sarah B. Goldberg,Xiuning Le,Zofia Piotrowska,Jonathan W. Goldman,Adrianus J. de Langen,Isamu Okamoto,Byoung Chul Cho,Paul D. Smith,Ilhem Mensi,Helen Ambrose,Silvija Kraljevic,Julie Maidment,Juliann Chmielecki,Xiaocheng Li-Sucholeiki,Gail Doughton,Gargi Patel,Phil Jewsbury,P. Szekeres,Jonathan W. Riess	2021	48
17	Prognostic impact of KRAS mutation status for patients with stage IV adenocarcinoma of the lung treated with first-line pembrolizumab monotherapy Lung Cancer ·Anneloes L. Noordhof,Ronald Damhuis,Lizza Hendriks,Adrianus J. de Langen,Wim Timens,Ben J.W. Venmans,Wouter H. van Geffen	2021	32
18	The force of HER2 – A druggable target in NSCLC? Cancer Treatment Reviews ·M. Jebbink,Adrianus J. de Langen,Mirjam C. Boelens,Kim Monkhorst,Egbert F. Smit	2020	54
19	Osimertinib treatment for patients with EGFR exon 20 mutation positive non-small cell lung cancer Lung Cancer ·Bianca van Veggel,Juliana F. Vilacha Madeira R Santos,Sayed M.S. Hashemi,Marthe S. Paats,Kim Monkhorst,Daniëlle A.M. Heideman,Matthew R. Groves,Teodora Radonic,Egbert F. Smit,Ed Schuuring,Anthonie J. van der Wekken,Adrianus J. de Langen	2019	60
20	Accuracy and Precision of Partial-Volume Correction in Oncological PET/CT Studies Journal of Nuclear Medicine ·Matthijs C. F. Cysouw,G. Krämer,Otto S. Hoekstra,Virginie Frings,Adrianus J. de Langen,Egbert F. Smit,Alfons J.M. van den Eertwegh,Daniela E. Oprea‐Lager,Ronald Boellaard	2016	30

About Adrianus J. de Langen

Adrianus J. de Langen is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research, having authored 64 papers that have together received 931 indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (48 papers), Lung Cancer Research Studies (17 papers), Colorectal Cancer Treatments and Studies (15 papers), Cancer Immunotherapy and Biomarkers (11 papers), Radiomics and Machine Learning in Medical Imaging (10 papers), Medical Imaging Techniques and Applications (10 papers), Lung Cancer Diagnosis and Treatment (10 papers) and Cancer Genomics and Diagnostics (10 papers). The work is most often cited by research in Oncology (599 citations), Pulmonary and Respiratory Medicine (527 citations) and Radiology, Nuclear Medicine and Imaging (278 citations). Adrianus J. de Langen has collaborated with scholars based in Netherlands, United States and Japan. Frequent co-authors include Egbert F. Smit, Ronald Boellaard, Otto S. Hoekstra, Anna-Larissa N. Niemeijer, Erik Thunnissen, Kim Monkhorst, Marc C. Huisman, Elisa Giovannetti, Godefridus J. Peters and Mirjam C. Boelens. Their work appears in journals such as Nature Medicine, Journal of Clinical Oncology and The Lancet Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact